CN101579306B - 环吡酮胺阴道栓剂及其制备方法 - Google Patents
环吡酮胺阴道栓剂及其制备方法 Download PDFInfo
- Publication number
- CN101579306B CN101579306B CN2009100163845A CN200910016384A CN101579306B CN 101579306 B CN101579306 B CN 101579306B CN 2009100163845 A CN2009100163845 A CN 2009100163845A CN 200910016384 A CN200910016384 A CN 200910016384A CN 101579306 B CN101579306 B CN 101579306B
- Authority
- CN
- China
- Prior art keywords
- ciclopirox olamine
- pessary
- substrate
- stearic acid
- castor oil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- MBRHNTMUYWQHMR-UHFFFAOYSA-N 2-aminoethanol;6-cyclohexyl-1-hydroxy-4-methylpyridin-2-one Chemical compound NCCO.ON1C(=O)C=C(C)C=C1C1CCCCC1 MBRHNTMUYWQHMR-UHFFFAOYSA-N 0.000 title claims abstract description 92
- 229960004375 ciclopirox olamine Drugs 0.000 title claims abstract description 92
- 238000002360 preparation method Methods 0.000 title claims description 29
- 239000003814 drug Substances 0.000 claims abstract description 37
- 239000000758 substrate Substances 0.000 claims abstract description 36
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims abstract description 28
- 235000021355 Stearic acid Nutrition 0.000 claims abstract description 25
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims abstract description 25
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims abstract description 25
- 235000010234 sodium benzoate Nutrition 0.000 claims abstract description 25
- 239000004299 sodium benzoate Substances 0.000 claims abstract description 25
- 239000008117 stearic acid Substances 0.000 claims abstract description 25
- 239000004359 castor oil Substances 0.000 claims abstract description 24
- 235000019438 castor oil Nutrition 0.000 claims abstract description 24
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims abstract description 24
- 239000000829 suppository Substances 0.000 claims description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 14
- 206010046914 Vaginal infection Diseases 0.000 claims description 13
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical group CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 claims description 8
- 238000001816 cooling Methods 0.000 claims description 8
- 238000010438 heat treatment Methods 0.000 claims description 8
- 239000000314 lubricant Substances 0.000 claims description 8
- 238000012856 packing Methods 0.000 claims description 8
- 229920001993 poloxamer 188 Polymers 0.000 claims description 8
- 229940044519 poloxamer 188 Drugs 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 238000010298 pulverizing process Methods 0.000 claims description 5
- 239000011324 bead Substances 0.000 claims description 3
- 230000000813 microbial effect Effects 0.000 claims description 3
- 238000007873 sieving Methods 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 17
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 239000000463 material Substances 0.000 abstract 1
- 238000012385 systemic delivery Methods 0.000 abstract 1
- 239000006216 vaginal suppository Substances 0.000 description 16
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 15
- 238000010521 absorption reaction Methods 0.000 description 15
- 210000001215 vagina Anatomy 0.000 description 15
- 229940120293 vaginal suppository Drugs 0.000 description 14
- 229940079593 drug Drugs 0.000 description 9
- 239000013558 reference substance Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 210000004877 mucosa Anatomy 0.000 description 8
- 229920000136 polysorbate Polymers 0.000 description 8
- 230000009471 action Effects 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- 229950008882 polysorbate Drugs 0.000 description 6
- 241000222122 Candida albicans Species 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- 241000283977 Oryctolagus Species 0.000 description 4
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 4
- 229920001983 poloxamer Polymers 0.000 description 4
- 229960000502 poloxamer Drugs 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 206010007134 Candida infections Diseases 0.000 description 3
- 239000001828 Gelatine Substances 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 230000002421 anti-septic effect Effects 0.000 description 3
- 201000003984 candidiasis Diseases 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 230000002045 lasting effect Effects 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- -1 polyoxyethylene monostearate Polymers 0.000 description 3
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010005913 Body tinea Diseases 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
- 208000010195 Onychomycosis Diseases 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 208000002474 Tinea Diseases 0.000 description 2
- 208000007712 Tinea Versicolor Diseases 0.000 description 2
- 206010067197 Tinea manuum Diseases 0.000 description 2
- 206010056131 Tinea versicolour Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 229940095731 candida albicans Drugs 0.000 description 2
- 229960001631 carbomer Drugs 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 229960004125 ketoconazole Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- 239000003229 sclerosing agent Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 201000003875 tinea corporis Diseases 0.000 description 2
- 201000004647 tinea pedis Diseases 0.000 description 2
- 201000005882 tinea unguium Diseases 0.000 description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
- 229940044959 vaginal cream Drugs 0.000 description 2
- 239000000522 vaginal cream Substances 0.000 description 2
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical class CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 description 1
- MIJDSYMOBYNHOT-UHFFFAOYSA-N 2-(ethylamino)ethanol Chemical compound CCNCCO MIJDSYMOBYNHOT-UHFFFAOYSA-N 0.000 description 1
- WDJHALXBUFZDSR-UHFFFAOYSA-N Acetoacetic acid Natural products CC(=O)CC(O)=O WDJHALXBUFZDSR-UHFFFAOYSA-N 0.000 description 1
- 241001480043 Arthrodermataceae Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000001387 Causalgia Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 description 1
- 241001337994 Cryptococcus <scale insect> Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 208000036649 Dysbacteriosis Diseases 0.000 description 1
- 208000027244 Dysbiosis Diseases 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 206010054152 Skin candida Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 206010042566 Superinfection Diseases 0.000 description 1
- 201000010618 Tinea cruris Diseases 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 201000008100 Vaginitis Diseases 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 201000007096 Vulvovaginal Candidiasis Diseases 0.000 description 1
- 208000010399 Wasting Syndrome Diseases 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000000680 avirulence Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- SCKYRAXSEDYPSA-UHFFFAOYSA-N ciclopirox Chemical compound ON1C(=O)C=C(C)C=C1C1CCCCC1 SCKYRAXSEDYPSA-UHFFFAOYSA-N 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 208000014439 complex regional pain syndrome type 2 Diseases 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000037304 dermatophytes Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000007140 dysbiosis Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 150000002990 phenothiazines Chemical class 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 235000011185 polyoxyethylene (40) stearate Nutrition 0.000 description 1
- 239000001194 polyoxyethylene (40) stearate Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 229960001755 resorcinol Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 239000002893 slag Substances 0.000 description 1
- 229960004025 sodium salicylate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
成分(100支) | 实施例1 | 实施例2 | 实施例3 | 对照品1 | 对照品2 | 对照品3 | 对照品4 | 对照品5 | 对照品6 | 对照品7 | 对照品8 |
环吡酮胺10g | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ |
硬脂酸(g) | 5 | 20 | 10 | 20 | 15 | 10 | 20 | ||||
氢化蓖麻油(g) | 30 | 2 | 15 | 20 | 30 | 12 | 25 | 30 | |||
苯甲酸钠(g) | 1 | 10 | 5 | 8 | 4 | 10 | 5 | 2 | |||
甘油明胶(g) | 100 | 300 | 450 | 300 | |||||||
聚乙二醇300(g) | 480 | 550 | 260 | ||||||||
聚山梨酯61(g) | 850 | 500 | 50 | ||||||||
泊洛沙姆188(g) | 700 | 800 | 750 | 50 | |||||||
可可豆脂(g) | 500 | 200 | |||||||||
大鼠阴道使 | 11.2 | 11.0 | 10.8 | 4.37 | 5.01 | 3.86 | 6.08 | 4.18 | 5.77 | 2.49 | 3.55 |
用24小时吸收情况(AUC)μg/.ml.h | |||||||||||
占口服全身吸收的百分率(%) | 93.3 | 91.3 | 90.0 | 36.4 | 41.7 | 32.2 | 50.7 | 34.8 | 48.1 | 20.7 | 29.6 |
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009100163845A CN101579306B (zh) | 2009-06-25 | 2009-06-25 | 环吡酮胺阴道栓剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009100163845A CN101579306B (zh) | 2009-06-25 | 2009-06-25 | 环吡酮胺阴道栓剂及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101579306A CN101579306A (zh) | 2009-11-18 |
CN101579306B true CN101579306B (zh) | 2011-04-27 |
Family
ID=41361715
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2009100163845A Expired - Fee Related CN101579306B (zh) | 2009-06-25 | 2009-06-25 | 环吡酮胺阴道栓剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101579306B (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103181888A (zh) * | 2011-12-30 | 2013-07-03 | 广西壮族自治区花红药业股份有限公司 | 一种环吡酮胺阴道栓剂 |
CN103932974B (zh) * | 2013-11-06 | 2017-01-11 | 山东诚创医药技术开发有限公司 | 一种环吡酮胺阴道栓组合物及其制备方法 |
CN104873459B (zh) * | 2015-06-04 | 2017-08-15 | 烟台荣昌制药股份有限公司 | 环吡酮胺阴道栓 |
CN109125427B (zh) * | 2018-11-12 | 2021-06-04 | 昆明积大制药股份有限公司 | 一种盆炎净栓剂及其制备方法 |
-
2009
- 2009-06-25 CN CN2009100163845A patent/CN101579306B/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN101579306A (zh) | 2009-11-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2408372C2 (ru) | Применение октенидина дигидрохлорида в полутвердых препаратах | |
HRP20050574A2 (en) | Pharmaceutical compositions of sertaconazole for vaginal use | |
US11865207B2 (en) | Topical pharmaceutical composition for treatment of anal fissures and hemorrhoids | |
CN101579306B (zh) | 环吡酮胺阴道栓剂及其制备方法 | |
JP2021014469A (ja) | ヘッジホッグ阻害性化合物の送達のための局所的製剤及びその使用 | |
CN101313904A (zh) | 一种用于治疗外阴道炎的芬替康唑栓剂 | |
CN101147725B (zh) | 一种用于阴道给药的酮康唑栓剂组合物 | |
WO2013029525A1 (zh) | 治疗皮炎的碘聚合物和糖皮质类固醇复方药物组合物 | |
CN110403935B (zh) | 一种治疗口腔溃疡的磷酸二酯酶-4抑制剂药物组合物及其制备方法 | |
CN102258785A (zh) | 一种缓释释药的药物载体 | |
TWI510243B (zh) | 用於治療膀胱癌的組成物及方法 | |
AU2013338140B2 (en) | Medicinal treatment of chronic dermal inflammatory diseases with norketotifen | |
CN102293735A (zh) | 一种抗真菌咪唑类药物缓释凝胶和制备方法 | |
ES2811365T3 (es) | Macrogols para aplicación a la mucosa, y sus usos terapéuticos | |
CN100551368C (zh) | 环吡酮胺凝胶剂、其制备方法及药物用途 | |
WO2023168948A1 (zh) | 白头翁皂苷b4在制备外用治疗银屑病药物中的应用 | |
RU2582278C2 (ru) | Трансдермальное средство для лечения и профилактики болезней суставов и мягких тканей, способ его получения и комбинированный трансдермальный препарат для лечения и профилактики болезней суставов и мягких тканей | |
JP2007077150A (ja) | 酸−酸緩衝系を含有する無水組成物 | |
RU2367469C2 (ru) | Фармацевтическая композиция для местного применения, обладающая антибактериальным и некролитическим действием, на основе лизоамидазы | |
CN113274500A (zh) | 神经激肽1受体抑制剂的外用制剂及其制备方法 | |
RU2367456C2 (ru) | Фармацевтическая композиция для местного применения, обладающая антибактериальным и некролитическим действием | |
CN101049286B (zh) | 含环吡酮胺的凝胶制剂 | |
CN104523711A (zh) | 酮康他索乳膏及其制备方法 | |
CN105796477A (zh) | 一种硝酸布康唑栓剂及其制备方法 | |
US20200230082A1 (en) | Topical acetaminophen formulations for itch relief |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: HAINAN YONGTIAN PHARMACEUTICAL INSTITUTE CO., LTD. Free format text: FORMER OWNER: WANG MING Effective date: 20130723 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 570125 HAIKOU, HAINAN PROVINCE TO: 570216 HAIKOU, HAINAN PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20130723 Address after: 570216 C03, Haikou Free Trade Zone, Hainan, China Patentee after: Hainan Yongtian Pharmaceutical Institute Co., Ltd. Address before: The new business building No. 48 570125 Hainan city of Haikou province China World Trade Center Road, room 2601 Patentee before: Wang Ming |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110427 Termination date: 20160625 |